📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK. (2025)

First Author: Borthwick N

Attributed to: Definition and induction of broadly protective responses against HIV-1 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.lanmic.2024.100956

PubMed Identifier: 39612921

Publication URI: http://europepmc.org/abstract/MED/39612921

Type: Journal Article/Review

Volume: 6

Parent Publication: The Lancet. Microbe

Issue: 3

ISSN: 2666-5247